A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma

Authors and Affiliations
Lisa I. Greene¹, Tullia C. Bruno², Jessica L. Christenson¹, Angelo D’Alessandro³,
Rachel Culp-Hill³, Kathleen Torkko¹, Virginia F. Borges⁴, Jill E. Slansky⁵, Jennifer K.
Richer¹*

¹ Department of Pathology, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. Aurora, CO 80045
² Department of Immunology, University of Pittsburgh, 5117 Centre Ave, Pittsburgh, PA 15213
³ Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. Aurora, CO 80045
⁴ Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. Aurora, CO 80045
⁵ Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. Aurora, CO 80045

Running Title
TDO2 and Tryptophan Catabolism in Breast Cancer

Keywords
TDO2, breast cancer, kynurenine, T cell, immunotherapy

Financial Support
DOD BCRP Award Number W81XWH-15-1-0039 to JKR and NRSA F31 Award Number CA203486-01A1 to LIG.

*Corresponding author
Jennifer K. Richer, Ph.D.
Department of Pathology
University of Colorado, Anschutz Medical Campus
12800 E 19th Ave Aurora, CO 80045, USA
Phone: (303) 724-3735
Fax: (303) 724-3712
Email: jennifer.richer@ucdenver.edu

Conflict of Interest Disclosure Statement
The authors declare no conflicts of interest.
Abstract: 206
Body of Text: 3604
Figures: 5
Supplementary Figures: 4
Supplementary Tables: 1

Abstract
Tryptophan catabolism is an attractive target for reducing tumor progression and improving antitumor immunity in multiple cancers. Tumor infiltration by CD8 T cells correlates with improved prognosis in triple-negative breast cancer (TNBC) and a significant effort is underway to improve CD8 T cell antitumor activity. In this study, primary human immune cells were isolated from the peripheral blood of patients and used to demonstrate that the tryptophan catabolite kynurenine induces CD8 T cell death. Furthermore, it is demonstrated that anchorage-independent TNBC utilizes the tryptophan catabolizing enzyme tryptophan 2,3-dioxygenase (TDO) to inhibit CD8 T cell viability. Publicly available data revealed that high TDO2, the gene encoding TDO, correlates with poor breast cancer clinical outcomes, including overall survival and distant metastasis-free survival, while expression of the gene encoding the more commonly studied tryptophan catabolizing enzyme IDO1 did not. Metabolomic analysis, using quantitative mass spectrometry, of tryptophan and its catabolites - including kynurenine - in the plasma from pre-surgical breast cancer patients (n=77) and 40 cancer-free donors (n=40) indicated a strong correlation between substrate and catabolite in both groups. Interestingly, both tryptophan and kynurenine were lower in...
the plasma from breast cancer patients compared to controls, particularly in women with
estrogen receptor (ER)-negative and stage-3 and -4 breast cancer.

**Implications**

Implications: This study underscores the importance of tryptophan catabolism,
particularly in aggressive disease, and suggests that future pharmacological efforts
should focus on developing drugs that target both TDO and IDO1.

**Introduction**

Triple-negative breast cancer (TNBC) is an aggressive disease that lacks FDA-
approved targeted therapies for the majority of patients (1). Importantly, TNBCs with
high levels of immune infiltrate have more favorable prognoses (2, 3). Specifically, a
high ratio of tumor-infiltrating cytotoxic CD8 T cells to immunosuppressive FoxP3+ T
regulatory cells correlates with improved breast cancer-specific survival in
chemoresistant TNBC (4). Indeed, TNBC has high expression of programmed cell death
1-ligand 1 (PD-L1) compared to other breast cancer subtypes, suggestive of evasion
from immune attack (5-7). Active clinical trials are investigating the efficacy of targeting
the PD-1/PD-L1 axis and other immune-directed interventions as treatments for TNBC;
however, results in TNBC patients treated with the anti-PD-1 agent pembrolizumab
indicate promising but limited efficacy (8, 9).

We previously discovered that aberrant expression and activity of the hepatic
tryptophan-catabolizing enzyme tryptophan-2,3-dioxygenase (TDO) in TNBC cell lines
supports anchorage-independent cell growth and late-stage metastasis through an
autocrine mechanism, whereby the tryptophan catabolite kynurenine activates the aryl-
hydrocarbon receptor (AhR) in the breast cancer cells (10). However, it is clear that
kynurenine also has suppressive paracrine effects on immune cells (11, 12). Most
studies have focused on the tryptophan catabolizing enzyme indoleamine-2,3-
dioxygenase (IDO) in cancer, and current inhibitors of this pathway in clinical trials only
target IDO activity. IDO transcript correlates with poor prognosis and increased
microvessel density in breast cancer (13). However, TDO2 (the gene encoding TDO), is
significantly higher in estrogen receptor (ER) negative (-) compared to ER+ breast
tumors and correlates with overall survival in breast cancer patients, suggesting a
potential failure of current tryptophan catabolizing agents in effectively targeting tumor
cell enzymatic activity (10). Importantly, recent negative clinical trial results in melanoma
(the ECHO-301 trial) and pancreatic cancer (ECHO-203), suggest that IDO inhibitors
are not sufficient for the reversal of tumor immune evasion (14) and indicate that it may
be necessary to target TDO as well.

Alterations in blood tryptophan and kynurenine levels have been examined in
multiple human cancers (15-17). Lower serum tryptophan correlates with poor
prognosis in melanoma, consistent with an increase in tryptophan catabolism (17). A
small-scale study showed that plasma from post-surgical (lumpectomy or mastectomy)
breast cancer patients has reduced tryptophan and elevated kynurenine compared to
cancer-free controls, as measured by ultra-high pressure liquid chromatography
(UHPLC), but importantly this study may not have been able to measure any potential
effects of the primary tumor on systemic levels of these molecules (15). Another breast
cancer study found relatively higher intratumoral kynurenine in ER- versus ER+ tumors
The issue of whether decreased tryptophan or increased kynurenine levels in breast cancer patient plasma reflect the activity of tumor tryptophan catabolizing enzymes remains unresolved.

Here, we demonstrate that kynurenine increased primary human CD8 T cell death and that conditioned media from anchorage-independent TNBC cells suppressed primary human CD8 T cell function in a TDO-dependent manner, suggesting a mechanism of enhanced immune evasion during metastasis. Furthermore, we quantified tryptophan and kynurenine – as well as a series of tryptophan catabolites – in plasma from 77 pre-surgical breast cancer patients using UHPLC-MS and detected significant differences in plasma from women with breast cancer versus no breast cancer, ER+ versus negative tumors, and with increasing disease stage.

Materials and Methods

Cell Culture

BT549 cells, purchased from ATCC in 2008 and authenticated prior to use by Short Tandem Repeat DNA Profiling (Promega), were grown in RPMI Medium 1640 with 10% fetal bovine serum (FBS), penicillin/streptomycin (P/S) and insulin supplementation. Suspension culture was achieved using plates coated with 12 mg/mL poly(2-hydroxyethyl methacrylate) (Sigma-Aldrich) reconstituted in 95% ethanol. Ethanol evaporated overnight, and plates were washed with PBS prior to use.

Primary Human T Cell Isolation and Activation

Blood was collected by venipuncture into tubes with heparin (BD Biosciences Vacutainer Systems) from donors with written informed consent under a University of
Colorado Anschutz Medical Campus Colorado Institutional Review Board (COMIRB)-approved protocol. Lymphocytes were isolated by adding 10 mL of Ficoll-Paque PLUS (GE Healthcare) per 20 mL of blood diluted in Hanks’ Balanced Salt Solution, then centrifuging at 2000 rpm for 25 minutes without deceleration. CD8 T cells were resuspended in PBS containing 0.5% BSA and 2 mM EDTA for selection using positive isolation kits (Dynabeads, Invitrogen). After isolation, cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) according to manufacturer’s instructions, then resuspended in RPMI medium containing 10% FBS, P/S, non-essential amino acids, sodium pyruvate, and HEPES. T cells were activated in plates coated with 0.5 µg/mL of CD3 antibody (clone OKT3, eBioscience) and 1.0 µg/mL of soluble CD28 antibody (clone CD28.2, eBioscience) for 5 days. For intracellular staining, T cells were stimulated for 4 hours after the activation using phorbol-12-myristate-13-acetate (PMA) at 20 ng/mL, ionomycin at 1 µg/mL, and GolgiStop (BD Biosciences).

**Cell Staining and Flow Cytometry**

T cells were stained with antibodies for CD3 (clone HIT3a, Biolegend) and CD8 (clone RPA-T8, Biolegend) at a 1:100 dilution and an intracellular stain for interferon gamma (clone 4S.B3, eBioscience) at a 1:50 dilution. Intracellular staining was achieved using an intracellular fixation and permeabilization buffer set (eBioscience). Dead cells were detected by positivity for a viability dye according to manufacturer’s instructions (Fixable Viability Dye BV421, eBioscience). Flow cytometry was conducted using an LSR II (BD Biosciences) and data were analyzed using FlowJo software (Tree Star, Inc).
TDO2 and AhR Inhibition

The TDO2 inhibitor 680C91 (Sigma-Aldrich) or the AhR antagonist CH-223191 (TOCRIS Bioscience) prepared in dimethyl sulfoxide (DMSO) were used.

Breast Cancer Patient Plasma

Blood and was acquired as described above from pre-surgical breast cancer patients with written informed consent under a COMIRB and HRPO approved protocol (COMIRB 15-2225 and HRPO A-18613). The characteristics of the cohort are described in Supplementary Table 1.

UHPLC-MS Targeted Metabolomic Analysis of Tryptophan Catabolism

Tryptophan (\(^{15}\text{N}_2\)) and kynurenine (ring-D\(_4\), 3,3-D\(_2\)) were purchased from Cambridge Isotope Laboratories, Incorporated. To ensure linearity over 5 orders of magnitude, lysis buffer (LB), a 5:3:2 ratio of MeOH:acetonitrile:H\(_2\)O, and 0.1% formic acid aliquots were each spiked with varying ranges of heavy-labeled tryptophan and kynurenine (50 μM, 5 μM, 500 nM, 50 nM, 5 nM, 500 pM) and analyzed by ultra-high pressure liquid chromatography coupled to mass spectrometry – UHPLC-MS. Plasma (20 μL) was extracted at 1:5 and 1:10 in LB containing 5 μM heavy labeled tryptophan and kynurenine as previously described, then diluted 1:5, 1:10 and 1:20 with H\(_2\)O and run on UHPLC-MS (18, 19). Sample extracts were analyzed via UHPLC-MS (Vanquish, Q Exactive – Thermo Fisher, Bremen, Germany) using C18 reverse-phase chromatography and positive electrospray ionization (ESI) (18, 20). A Kinetex C18
column, 2.1 x 150 mm, 1.7 μm particle size (Phenomenex) was used and equipped with a C18 guard column (Phenomenex). The method is a variant of previously published methods (21). Samples were resolved at 45°C with a gradient elution over 4 minutes, flowing at 450 μL/min. Mobile phase A is 0.1% formic acid in water, mobile phase B is 0.1% formic acid in acetonitrile. 5% B and 95% A is held from 0.00–0.50 minutes. From 0.50–1.10 minutes, B increases to 95% B and 5% A. This condition is held from 1.10–2.75 minutes. From 2.75–3.00 minutes A decreases to the initial condition of 5% B and 95% A and is held from 3.00–4.00 minutes. The Q Exactive mass spectrometer was operated in positive ion mode using electrospray ionization, scanning in Full MS mode (1 μscan) from 100 to 1500 m/z at 70,000 resolution, with 4 kV spray voltage, 45 sheath gas, 15 auxiliary gas. Calibration was performed prior to analysis using the Pierce Positive Ion Calibration Solution (Thermo Fisher Scientific). Metabolite assignments and heavy isotopologue detection for absolute quantitation against internal standards were determined against in house standard libraries and KEGG database searches through Maven (22). Technical reproducibility was assessed by monitoring internal heavy labeled standard mixes as reported (18). Calculation of absolute quantification for measured metabolites was performed using the following formula: [light] = (abundance light) / (abundance heavy) * [heavy] (dilution factor) where dilution factor is 10 for an extraction of 10 μL plasma in 90 μL lysis buffer.

Statistical Analyses
Results

Primary human CD8 T cell response to kynurenine and cancer cell conditioned media

Infiltration into breast tumors by cytotoxic CD8 T cells correlates with improved prognosis in ER- breast cancer (4, 23-25). To test the effect of kynurenine on primary human peripheral blood cytotoxic T cells, CD8+ cells isolated from peripheral blood of healthy human donors (Figure 1A) were treated with increasing doses of kynurenine over a 5-day T cell receptor (TCR) activation protocol. At 50 and 100 µM kynurenine, CD8 T cell death increased as measured by a fixable viability dye (Figure 1B), while CFSE analysis of live CD8 T cells indicated no change in proliferation (Figure 1C), demonstrating a direct impact of kynurenine specifically on human CD8 T cell viability.

To test whether kynurenine acts through AhR to affect CD8 T cell viability, CD8 T cells were treated with increasing doses of kynurenine with or without the AhR antagonist CH-223191 (26). Treatment with CH-223191 significantly reduced the cytotoxic effect of 50 µM kynurenine (Figure 1D-E), indicating that kynurenine acts in part on CD8 T cells through AhR.

We previously reported that TNBC cells surviving under anchorage-independent culture conditions increased expression and activity of TDO, resulting in increased intracellular and secreted kynurenine (10). In the present study, we asked whether such
anchorage-independent cells have enhanced immune evasion. BT549 TNBC cells were cultured in attached (ATT) or suspended (SUS) conditions for 24 or 48 hours. Primary human CD8 T cells were cultured in these conditioned media (CM) with CD3 and CD28 antibodies for 5 days. CD8 T cells cultured in SUS CM were less viable than those cultured in ATT CM (Figure 2A). Since kynurenine decreased interferon-gamma (IFNγ) mRNA in murine cytotoxic T cells (27), we tested whether CM from attached versus suspended TNBC cells would affect primary human CD8 T cell production of IFNγ. Indeed, the SUS CM significantly reduced IFNγ production compared to ATT CM (Figure 2B and 2C). To determine if the effects of SUS CM were due to increased TDO activity, TNBC cells were plated in ATT or SUS conditions with or without TDO-specific inhibitor 680C91 for 48 hours. While SUS CM again increased CD8 T cell death, this effect was significantly abrogated when SUS cells were treated with TDO inhibitor 680C91 (Figure 2D), suggesting that TDO activity is at least partially responsible for the CM effect. However, treating the CD8 T cells with the AhR antagonist CH-223191 did not rescue the effect of SUS CM, suggesting additional effects of TNBC TDO2 activity on the CD8 T cells (Figure 2E).

**TDO2 RNA expression correlates with breast cancer outcomes, and tryptophan catabolism is altered in breast cancer**

We previously reported that TDO2 is significantly higher in breast cancer versus normal breast tissue and in ER-negative versus ER-positive disease, and that above-median TDO2 correlated with poor overall survival in the Curtis et al dataset (a dataset containing gene expression analysis from 2000 breast tumors, extracted through the
data-mining platform Oncomine) (10, 28). In the current study, we used the KM Plotter tool to investigate breast cancer outcomes associated with both TDO2 and IDO1 expression (29). High TDO2 in primary breast cancer correlated with worse overall survival and reduced distant metastasis-free survival (Figure 3A), while IDO1 did not (Figure 3B). Consistent with our findings that breast cancer cells have elevated tryptophan catabolism during anchorage independence, we also found, using the Curtis et al dataset (28), that the gene encoding the amino acid transporter LAT1 (SLCA5) (which uptakes tryptophan and other large neutral amino acids from the microenvironment into the cell) was significantly elevated in breast cancer versus normal breast (Supplemental Figure 1A), in ER-negative versus ER-positive disease (Supplemental Figure 1B), and in higher grade breast cancer (Supplemental Figure 1C). We also found using the Curtis et al dataset and KM Plotter tool that above-median LAT1 was associated with worse overall (Supplemental Figures 1D-E) as well as distant metastasis-free (Supplemental Figure 1F) survival as compared to below-median.

To further understand how tryptophan catabolism is altered in breast cancer subtypes, we measured plasma concentrations of tryptophan and its main catabolites, including kynurenine using UHPLC-MS (Supplementary Table 1). In the plasma from cancer-free “normal” women, the concentration of tryptophan ranged from 69.50-294.49 µM, while in women with breast cancer the range was 38.04-260.77 µM. Meanwhile, the plasma concentration of kynurenine in normal women ranged from 3.46-13.61 µM, and from 2.19-19.83 µM in women with breast cancer. Strikingly, there was a significant positive correlation between tryptophan and kynurenine both in plasma from normal women (Figure 4A) and women with breast cancer (Figure 4B). A comparison of the
plasma concentrations of tryptophan and kynurenine in women with breast cancer versus normal controls demonstrated that women with breast cancer had significantly reduced tryptophan (mean = 141.39 µM) compared to normal (mean = 173.32 µM) (Figure 4C). Interestingly and surprisingly, the concentration of kynurenine was also significantly lower in the plasma of women with breast cancer (mean = 7.12 µM) compared to normal controls (mean = 9.02 µM) (Figure 4D).

Given previous reports that \textit{TDO2} is significantly higher in ER- versus ER+ disease, the plasma tryptophan and kynurenine concentrations in women with ER- and ER+ breast cancer were next compared (10). There was no significant difference in either plasma tryptophan or kynurenine in women with ER+ and ER- disease (Figure 4C-D), though lower levels of tryptophan and anthranilate were observed in plasma from women with ER-, HER2- disease (Supplemental Figure 2). However, ER- breast cancer patients had significantly reduced plasma tryptophan compared to normal controls, while ER+ breast cancer patients did not (Figure 4C). Plasma kynurenine from both ER- and ER+ breast cancer subsets was significantly lower than that from normal controls (Figure 4D). Of note, these decreases were more marked in women with non-pregnancy-associated breast cancer (PABC) in comparison to PABC patients (where PABC is defined as a diagnosis with 5 years of pregnancy), with the highest relative levels of tryptophan (and its catabolites hydroxytryptophan, kynurenine and kynurenic acid) detected in normal women who did not give birth within the past 5 years.

Interestingly, women without a cancer diagnosis (normal), who had not given birth within the past five years, had intermediate levels of tryptophan and its catabolites in between
the levels observed in normal women who had given birth within the past five years and PABC/non-PABC patients (Supplementary Figure 3).

To examine whether either plasma tryptophan or kynurenine correlated with breast cancer aggressiveness, breast cancer stage at diagnosis was used. Both tryptophan (Figure 4E) and kynurenine (Figure 4F) were significantly lower in stage 3/4 breast cancer patient plasma than in plasma from normal controls, while there was no difference in either tryptophan or kynurenine when comparing stage 0/1 patients versus normal (Figure 4E-F). Interestingly, there was also a decrease in the kynurenine catabolite kynurenic acid in stage 3/4 breast cancer patients compared to patients with stage 1/2 disease (Supplementary Figure 4).

Our finding that both tryptophan and kynurenine were reduced in the plasma of breast cancer patients versus normal controls led us to investigate whether there were differences in nicotinamide, the final metabolite in the kynurenine pathway of tryptophan catabolism, between breast cancer patient and normal plasma. To do this, we calculated the ratio of tryptophan/nicotinamide in our dataset. We found that the tryptophan/nicotinamide ratio was significantly lower in the plasma from breast cancer patients compared to normal controls, suggesting a potential overall increase in tryptophan catabolism not limited to the conversion of tryptophan to kynurenine (Figure 4G). While the average relative abundance of nicotinamide was slightly elevated in breast cancer patient plasma compared to controls, this difference was not statistically significant (Figure 4H). However, the ratio, which represents each individual’s substrate (tryptophan) versus metabolite, is likely more meaningful given the person to person variability.
To examine whether tryptophan catabolism correlated with outcomes in this breast cancer data set, we divided the patient data into tryptophan-low and tryptophan-high groups based on the median concentration of plasma tryptophan, and compared the progression-free survival of these groups, where progression was defined as local, regional, or distant recurrence, or patient death. While there was no significant difference in progression-free survival between these groups in breast cancer patients with either ER+ (Figure 5A) or ER- (Figure 5B) disease, there was a trend which did not reach statistical significance towards patients with lower than median plasma tryptophan having poorer outcomes (Figure 5B), consistent with a negative impact of reduced tryptophan in ER- disease.

Discussion

While tryptophan catabolism is known to mediate tumor immune evasion, the impact of IDO or TDO activity on CD8 T cells was thought to occur through indirect suppression via regulatory T cell activation. We demonstrate here that the direct impact of kynurenine on primary human CD8 T cells is to reduce viability in the setting of activation through the T cell receptor. We previously reported that TDO activity increased in TNBC cell lines under anchorage-independent conditions, resulting in increased intracellular and secreted kynurenine (10). Critically, we show here that conditioned media from TNBC cells cultured under anchorage-independent conditions decreases the viability and IFNγ production of primary human CD8 T cells, and that this effect is abrogated by the specific TDO inhibitor 680C91, indicating that anchorage-independent TNBC cells are highly immunosuppressive in part through TDO-mediated
A high ratio of cytotoxic CD8 T cells to Treg cells correlates with improved clinical outcomes in TNBC (30, 31). Thus, the power of TDO-positive metastatic TNBC cells to suppress CD8 T cells both directly and indirectly via the induction of Tregs (12) could critically contribute to disease progression. Interestingly, the concentration of kynurenine in the conditioned media was lower than the concentration of purified kynurenine that reduced CD8 T cell viability, a phenomenon which could be explained by the milieu of other factors that are secreted by suspended TNBC cells which might have immune-modulatory effects (10).

Although inhibition of TDO activity in suspended TNBC cells abrogated the effects of conditioned media on the viability and function of CD8 cells, inhibition of the receptor for kynurenine, AhR, in the CD8 cells was not sufficient to mitigate this effect. One possible explanation for the differential effects of TDO as compared to AhR inhibition is that the effect of TDO activity on CD8 T cells is due to the combined effects of both tryptophan depletion and kynurenine secretion. Kynurenines combined with tryptophan depletion downregulates the TCR zeta-chain and decreases cytokine production in murine CD8 T cells (27), and IDO-mediated tryptophan depletion inhibits mTOR and PKC-θ activation to induce murine T cell anergy and autophagy (32). AhR antagonism would interfere with kynurenine-mediated AhR activation, but would not abrogate tryptophan depletion.

To our knowledge, the present study includes the largest metabolomic analysis of tryptophan and kynurenine in plasma from pre-surgery breast cancer patients, allowing assessment of the impact of an existing breast tumor on systemic tryptophan and kynurenine levels. Given that others have reported higher kynurenine and lower
tryptophan levels in breast cancer patients compared to healthy donors (15), our finding of a strong maintenance of balanced levels of substrate to catabolite in plasma from both breast cancer patients and cancer-free donors was unexpected. This may be attributable to the strong ability of the kidneys to handle increased kynurenine and it is documented that increased TDO/IDO activity does not necessarily result in increased plasma kynurenine (33, 34). Interestingly, we found that compared to healthy donors, tryptophan was only significantly lower in the plasma of patients with ER-negative tumors. This finding suggests a particularly important role of elevated tumor tryptophan catabolism in ER-negative disease. An expanded follow-up metabolomic study that includes more patients with ER- and stage 3/4 disease is imperative to determine if plasma tryptophan and kynurenine reflect tumoral enzymatic activity and correlate with outcome. Although currently limited by lack of quality antibodies for IHC, it is likely that measurement of TDO/IDO protein levels or activity in primary tumor and/or circulating tumor cells would be more informative than plasma levels of tryptophan and kynurenine. Additionally, levels of the enzymes in tumors should be correlated with tumor-infiltrating lymphocyte composition in future studies. It is possible that further flux through the kynurenine pathway in tumor cells could account for the comparatively low kynurenine concentration in plasma from women with breast cancer. In a previous study, we found that expression of KYNU, the gene encoding kynureninase (an enzyme downstream of TDO) is elevated in suspended TNBC cell lines and in the context of increased inflammatory signaling (10), which would be consistent with tryptophan catabolism further down the pathway. Indeed, our finding that the tryptophan/nicotinamide ratio was significantly reduced in breast cancer patient plasma compared to controls is consistent
with the possibility of an overall increase in tryptophan catabolic activity not limited to 
the initial step in the pathway. Metabolomic tracing of tryptophan could help elucidate 
the ultimate fate of this amino acid in tumors. Development of better antibodies to 
measure TDO and IDO or gauge activity will be a significant hurdle to overcome in the 
quest for biomarkers indicative of patients who may benefit from tryptophan catabolism-
targeted therapies.

Acknowledgements

The authors wish to thank the University of Colorado School of Medicine Biological 
Mass Spectrometry Core Facility for their contributions to this manuscript. We also 
acknowledge the shared resources of the University of Colorado Cancer Center NCI 
Support Grant (P30CA046934), particularly the Tissue Culture Core. We thank Emily 
Rozzo and Michelle Borkove for assistance in patient sample collection and analysis 
guidance. Finally, we thank the blood donors that made these studies possible.
References


**Figure Legends**

**Figure 1:** Increased kynurenine leads to primary human CD8 T cell death, which is reversed by an AhR antagonist. (A) Representative example of gating strategy for flow cytometric analysis: CD8 T cells were gated based on double positivity for CD8 (PE-Cy7) and CD3 (PerCP-Cy5.5). Cell death was determined by positive staining for the fixable viability stain BV421. Proliferation was measured by CFSE dilution. (B) Cells were activated with CD3 and CD28 antibodies for 5 days in the indicated concentration of kynurenine and CD8 T cell death was determined. Each dot represents cells from one human donor. N=9 donors, mean with standard deviation, one-way ANOVA. (C) Cells were treated with kynurenine as described in (B) and assayed for CD8 T cell proliferation. N=9 donors, one-way ANOVA. (D) Representative images (10x magnification) of CD8 T cells on activation Day 5 that were treated with indicated concentrations of kynurenine and either 10 µM of the AhR antagonist CH-223191 (AhRa) or DMSO. (E) CD8 T cells were activated, treated with 10 µM AhRa or vehicle control (DMSO), and assayed for cell death. N=6, mean with standard deviation, paired t-tests.

**Figure 2:** The effect of conditioned media from suspended TNBC cells on primary human CD8 T cells is similar to that of purified kynurenine, and is reversed by TDO2 inhibitor 680C91. (A) Conditioned media was collected from BT549 TNBC cells grown in attached (ATT) or suspended (SUS) culture conditions for either 24 or 48 hours as indicated. CD8 T cells were isolated from the blood of normal donors and activated for 5 days with CD3 and CD28 antibodies in the conditioned media. Each line
represents the response of CD8 T cells from one donor. Cell death was measured as described in Figures 1A and B. N=9, paired t-tests. (B) Representative flow cytometric analysis of CD8 T cells for IFNγ production is shown. (C) IFNγ production by CD8 T cells cultured in conditioned media for 48 hours. N=7, paired t-tests. (D) CD8 T cells were activated in conditioned media and either 0.1 µM 680C91 (to inhibit TDO activity) or vehicle control (DMSO). Each line represents the response of CD8 T cells from one human volunteer donor. N=5, paired t-tests. (E) CD8 T cells were activated in conditioned media and treated with either 10 µM CH-223191 (to inhibit AhR activation) or vehicle control (DMSO). N=5, paired t-tests.

Figure 3: TDO2 expression correlates with breast cancer outcomes, while expression of the more commonly studied IDO1 does not. (A) Patients were split into TDO2-high (red, n=699) or TDO2-low (black, n=703) groups based on median TDO2 gene expression. Overall survival (left) and distant metastasis-free survival (right) was plotted using KmPlot.com. (B) Patients were split into IDO1-high (red, n=701) or IDO1-low (black, n=701) groups based on median gene expression, and overall survival and distant-metastasis free survival was plotted. N=1402, hazard ratios are given with 95% confidence intervals, logrank test.

Figure 4: Tryptophan and kynurenine are reduced in breast cancer plasma. Ultra-high performance liquid chromatography/mass spectrometry was used to measure tryptophan and kynurenine concentrations and nicotinamide abundance in the plasma from normal women and women with breast cancer. The concentrations of tryptophan
and kynurenine correlate significantly and positively in both normal (A) (n=40) and breast cancer patient (B) (n=77) plasma by Pearson and Spearman tests. Comparison of tryptophan (C) and kynurenine (D) concentrations in plasma from normal women, all breast cancer patients in the cohort, and ER+ versus ER- breast cancer patients. Mean with standard deviation, *p<0.05, **p<0.01, one-way ANOVA and Tukey's multiple comparisons test. Comparison of tryptophan (E) and kynurenine (F) concentrations plotted by breast cancer stage is shown. Mean with standard deviation, one-way ANOVA and Tukey's multiple comparisons test. (G) Comparison of the ratio of tryptophan (TRP) to nicotinamide between plasma from normal women and women with breast cancer. Mean with standard deviation, **** p<0.0001, unpaired t-test. (H) Comparison of the relative abundance of nicotinamide in the plasma from normal and breast cancer patient plasma. Mean with standard deviation, p=0.11, unpaired t-test.

Figure 5: Breast cancer patient plasma tryptophan and progression-free survival.

Ultra-high performance liquid chromatography/mass spectrometry was used to measure tryptophan concentrations in the plasma from women with breast cancer. Kaplan-Meyer curves plotting progression-free survival of breast cancer patients with ER+ disease (n=49) (A) or ER- disease (n=28) (B) are shown, where progression was defined by local, regional, or distant recurrence, or patient death in the years after surgery. Logrank test.
Figure 3

A

**Overall Survival**

\[ HR = 1.44 \ (1.16-1.8) \]
\[ \text{Logrank} \ P = 0.0011 \]

---

**Distant Metastasis-Free Survival**

\[ HR = 1.67 \ (1.37-2.05) \]
\[ \text{Logrank} \ P < 0.0001 \]

---

**TDO2 Expression**

- Low
- High

---

**Time (months)**

B

**IDO1 Expression**

\[ HR = 0.85 \ (0.68-1.06) \]
\[ \text{Logrank} \ P = 0.14 \]

---

**Time (months)**

\[ HR = 0.97 \ (0.79-1.18) \]
\[ \text{Logrank} \ P = 0.76 \]

---

**Time (months)**
Figure 4

A

B

C

D

E

F

G

H

Pearson $r=0.72$, $p<0.0001$
Spearman $r=0.69$, $p<0.0001$

Pearson $r=0.81$, $p<0.0001$
Spearman $r=0.69$, $p<0.0001$

Tryptophan [μM]

Tryptophan [μM]

Tryptophan [μM]

Tryptophan [μM]

Tryptophan [μM]

Tryptophan [μM]

Tryptophan [μM]

TRP/Nicotinamide Ratio

Nicotinamide (Relative Abundance)

ns

* $p<0.05$

** $p<0.01$

**** $p<0.0001$

Downloaded from mcr.aacrjournals.org on November 11, 2021. © 2018 American Association for Cancer Research.
Figure 5

A

ER+

% progression-free survival

Years since surgery

Tryptophan

Logrank=0.82

n=49

Low

High

B

ER-

% progression-free survival

Years since surgery

Tryptophan

Logrank=0.17

n=28

Low

High
Molecular Cancer Research

A Role for Tryptophan-2,3-dioxygenase in CD8 T Cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma


Mol Cancer Res  Published OnlineFirst August 24, 2018.

Updated version  Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-18-0362

Supplementary Material  Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2018/08/24/1541-7786.MCR-18-0362.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://mcr.aacrjournals.org/content/early/2018/08/24/1541-7786.MCR-18-0362. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.